Overview

Study Assessing Single and Multiple Doses of IDX21459 in Healthy and HCV-Infected Subjects

Status:
Terminated
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
A multi-part study to evaluate the safety and PK of single ascending doses of IDX21549 in healthy and HCV-infected subjects. The effect of food on the PK of IDX21549 will also be evaluated. Antiviral activity will also be assessed in HCV-infected subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.